DNA promoter hypermethylation leads to a lack of CD19 expression, which is associated with resistance of chronic lymphocytic leukemia (CLL) to CD19 CAR-T cell therapy, and this situation can be reversed by treatment with a demethylating agent (29). This evidence concerns the gene CD19 and B-cell chronic lymphocytic leukemia.